Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 6, 2026

Coursera outlines $805M-$815M 2026 revenue target as Udemy merger and AI initiatives accelerate platform evolution

View original at seekingalpha.com
Coursera outlines $805M-$815M 2026 revenue target as Udemy merger and AI initiatives accelerate platform evolution Earnings Call Insights: Coursera, Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The total number of paid Enterprise customers increased to 1,730, up 7% from a year ago, and net retention rate for paid enterprise customers was 93%

    80% confidence
  • There is no change to Consumer pricing or Enterprise pricing from the platform fee

    80% confidence
  • For the full year, net income was $67 million or 8.8% of revenue and adjusted EBITDA was $64 million, representing an 8.4% margin

    80% confidence
  • The new 15% platform fee will gradually benefit margins, with initial expansion in the Consumer segment in the second half of 2026 and Enterprise margin improvement expected in 2027

    80% confidence
  • We do expect to continue to make improvements and progress on gross margin in the aggregate

    80% confidence
  • Q4 delivered total revenue of $197 million, up 10% from the prior year period, driven by growth across both Consumer and Enterprise segments

    80% confidence
  • The Udemy merger is an important step in accelerating Coursera's strategy and reinforcing the shift toward a leading technology platform for skills

    80% confidence
  • We won't be happy with our NRR number until it's frankly above 100%

    80% confidence
  • Coursera delivered a strong fourth quarter with full-year revenue of $757 million, a 9% increase year-over-year

    80% confidence
  • The platform fee is expected to provide a structural benefit to gross margin over time

    80% confidence
  • Consumer segment growth is projected at more than 10% for 2026, with Enterprise expected to grow in the low single digits

    80% confidence
  • Traffic from AI platforms is described as early days with higher-intent traffic but no substantive data yet

    80% confidence
  • Guidance for Udemy merger closing remains the second half of the year but acknowledged a wide range of possible outcomes

    80% confidence
  • Partner feedback on the Udemy merger has been generally positive with questions about integration

    80% confidence
  • The platform fee is to enable us to invest in an ongoing way in continuing to improve the platform

    80% confidence
  • The company achieved record free cash flow of $78 million, up 32%

    80% confidence
  • The platform offered more than 13,500 courses, expanding the catalog by over 45% year-over-year, the fastest pace in the past 5 years

    80% confidence
  • We anticipate revenue to be in the range of $805 million to $815 million for full year 2026, representing growth of approximately 6% to 8% from the prior year

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Coursera outlines $805M-$815M 2026 revenue target as Udemy merger and AI initiatives accelerate platform evolution — Source | Via News | ViaNews Market